FIGURE 6.

GW6471 decreased intestinal fatty acid uptake and improved obesity and NASH depending on the presence of intestinal FABP1. (A,B) The anti‐NAFLD effect of GW6471 in Fabp1 ^∆IE and Fabp1 ^fl/fl mice. (A) Representative H&E and Oil Red O staining; scale bar 100 µm. (B) Liver weight and liver ratio, hepatic TC and TG, and serum ALT, TC, TG, and NEFA of 16‐week‐HFD‐fed mice (n = 5), postprandial serum TG levels (n = 5) and fecal NEFA levels (n = 7) at 1 week after GW6471 dosing. (C) Intestinal FABP1 protein levels. (D) NBD‐stearate (left) or BODIPY‐C₁₂ (right) uptake in intestinal organoids (n = 4). (E) NBD‐stearate (left) or BODIPY‐C₁₂ (right) uptake in intestinal organoids infected with Lv‐ctrl or Lv‐Fabp1 (n = 4). *p < 0.05; **p < 0.01, ***p < 0.001. (B) Postprandial serum TG, ^# p < 0.05, ^## p < 0.01, Fabp1 ^∆IE vehicle group versus Fabp1 ^fl/fl vehicle group; *p < 0.05, **p < 0.01, ***p < 0.001, Fabp1 ^fl/fl vehicle group versus Fabp1 ^fl/fl GW6471 group. Lv‐Ctrl, control lentivirus; Lv‐Fabp1, lentivirus that carries the mouse Fabp1 cDNA